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Abstract Miniaturized electrochemical in vivo biosensors al-
low the measurement of fast extracellular dynamics of neuro-
transmitter and energy metabolism directly in the tissue.
Enzyme-based amperometric biosensing is characterized by
high specificity and precision as well as high spatial and tem-
poral resolution. Aside from glucosemonitoring, many systems
have been introduced mainly for application in the central ner-
vous system in animal models. We compare the microsensor
principle with other methods applied in biomedical research to
show advantages and drawbacks. Electrochemical sensor sys-
tems are easily miniaturized and fabricated by microtechnology
processes. We review different microfabrication approaches for
in vivo sensor platforms, ranging from simple modified wires
and fibres to fully microfabricated systems on silicon, ceramic
or polymer substrates. The various immobilization methods for
the enzyme such as chemical cross-linking and entrapment in
polymer membranes are discussed. The resulting sensor perfor-
mance is compared in detail. We also examine different con-
cepts to reject interfering substances by additional membranes,
aspects of instrumentation and biocompatibility. Practical con-
siderations are elaborated, and conclusions for future develop-
ments are presented.
Keywords In vivo . Biosensor . Chemical sensor .
Microfabrication . Glutamate . Lactate
Introduction
The measurement of metabolic parameters by microsensors
directly within the tissue can be a valuable tool in biomedical
research and holds much promise for clinical practice. Unlike
the measurement of electrical signals in neural recording,
modified microelectrodes can be used as chemical sensors to
detect concentrations of chemicals such as energy metabolites
or neurotransmitters. These chemical sensors are biosensors if
enzymes with their very specific interaction with a substrate
are immobilized as biological recognition elements onto such
electrodes. This method allows the fabrication of selective,
amperometric electrochemical sensors, where a potential is
applied and the measured current is proportional to the analyte
concentration. Microsensors are self-contained, chemical and
biosensor devices miniaturized to functional dimensions of
typically tens to hundreds of micrometres, and have an elec-
trical output signal in our case.
The most widely studied in vivo sensors are continuous
glucose monitoring systems aimed at patients with metabolic
disorders (e.g. diabetes). However, they have been covered
extensively in the literature, in terms of both theory and prac-
tical applications [1–3] and will therefore not be the focus of
this article. The other main driving force behind in vivo sen-
sors is the neurosciences. Many microsensors have been de-
veloped for short-term brain application in animal models,
mostly for neurotransmitters (e.g. glutamate or choline) and
energy metabolites (e.g. lactate). Here, the focus is shifted
more towards basic biomedical research. Application has been
limited to animals so far, in contrast to the use of continuous
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Electrochemical sensor systems are easily miniaturized and
fabricated with microfabrication technologies. Small, repro-
ducible electrode geometries on thin, needle-type probes can
be achieved, resulting in a high spatial resolution and minimal
sensor footprint. A number of powerful fabrication tools used
in microsystems engineering are available. Enzyme-based,
amperometric, electrochemical biosensing allows a highly se-
lective and sensitive response in a complex environment. In
contrast to other techniques such as microdialysis and nuclear
magnetic resonance (NMR) spectroscopy, microsensors can
rapidly and precisely measure extracellular low analyte con-
centrations within the tissue in near real time. From both an
engineering point of view and a sensor development point of
view, we discuss sensor principles and microsensor platforms.
Because of the countless different biosensor principles, ever-
evolving electrode materials and electrochemical methods, we
focus on those concepts that have been successfully trans-
ferred to self-contained microsensor platforms for actual in
vivo use. Non-enzymatic in vivo sensors (e.g. for the detection
of the monoamine neurotransmitters dopamine and serotonin,
where the analyte is electroactive and can be converted direct-
ly at the electrode) are not discussed either [4–7].
In this article, we describe and compare different platform
and sensor integration technologies for enzyme-based ampero-
metric in vivo microsensors, discussing work relevant to the
current state of the art regarding fabrication and performance.
We compare the microsensor approach with other techniques to
illustrate where such sensors can be applied, what advantages
can be expected and how they complement other methods. We
describe the different microfabrication techniques for ampero-
metric in vivo sensors, ranging from simple modified wires and
fibres to fully microfabricated systems on silicon, ceramic or
polymer substrates. We discuss recent developments (e.g. in
silicon and flexible microtechnology). The various immobiliza-
tion methods for the enzyme are compared, as are their impli-
cations for sensor performance, where a detailed literature re-
view is included. We also describe different concepts to reject
interfering substances, to provide selectivity and to provide
biocompatibility. Practical considerations are elaborated and
conclusions for future developments are presented.
Background
Metabolism and relevance of measured parameters
Glutamate and neurotransmitters
Glutamate is well known as the main excitatory neurotrans-
mitter in the central nervous system (CNS). It is involved in
many aspects of neuronal functions and diseases thereof. In a
simple description, glutamate and other neurotransmitters are
stored inside neurons in relatively high concentrations, around
10 mM in the case of glutamate [8, 9]. On activation of neu-
rotransmission, they are quickly released into the synaptic
cleft, where they propagate the signal across the synapse. To
maintain a high signal-to-noise ratio of the synaptic transmis-
sion, neurotransmitters are cleared from the extracellular space
rapidly by efficient uptake mechanisms. Glutamate is taken up
mainly by astrocytes, converted to glutamine and shuttled
back to the neurons. The physiological extracellular back-
ground concentration for neurotransmitters in the CNS is only
in the low micromolar range. This difference from the intra-
cellular value serves as a good example why volume methods
such as NMR spectroscopymeasure entirely different concen-
trations compared with measurements in the extracellular
space. Elevated extracellular glutamate concentrations also
lead to neuronal death. From the dimensions of the synaptic
cleft (300 μmwidth, 20 nm gap [10]) and the timeframe (mil-
liseconds [11]) in which high concentrations (1 mM [10, 11])
are present there, it is clear that current amperometric
microsensors cannot aim at measuring Bsynaptic^ neurotrans-
mitters, but rather can aim at changes in the extrasynaptic
background. Neurotransmitters also have a multitude of func-
tions beyond synaptic neurotransmission [9]. Furthermore, the
glutamate–glutamine cycle is the main energy consumer in the
CNS, underlining the relationship between energy and neuro-
transmitter metabolism [12, 13].
Energy metabolites
Glucose as the primary energy source for cells is normally
supplied to most tissues through the bloodstream in relatively
high and stable concentrations (4–6 mM), especially the brain
(1–3 mM) [14]. Lactate is the main product of anaerobic me-
tabolism. Besides being a direct indicator for the amount of
anaerobic metabolism, it is more than a metabolic waste prod-
uct. It can act as a neuroprotector and under certain conditions
as an energy substrate [15]. Especially the lack of oxygen (e.g.
because of stroke or trauma) can lead to the breakdown of
neurotransmitter metabolism, with understandably severe
consequences. In an ageing society, ischaemic stroke has an
increasingly larger share among the causes of death and ac-
quired disabilities with a high socioeconomic relevance [16,
17]. A focus of research is also the battle against the numerous
neurodegenerative diseases, where alterations in neurotrans-
mitter metabolism are often observed [18]. It is therefore quite
obvious that the fast, precise and extracellular measurement of
metabolic parameters is of interest in fields ranging from fun-
damental biomedical research to clinical intensive care.
Although the measurement of neurotransmitters outside the
CNS does not play a large role, that of energy metabolism
does. Changes in cellular metabolism are closely linked to
cancer. Inside tumours a hypoxic environment with a highly
anaerobic metabolism is often found [19, 20]. Any disruption
in blood supply and thus oxygen and energy supply (e.g.
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during surgery, transplantations, sepsis or trauma) will lead to
alterations in metabolism. Here another field of activity for
microsensors may evolve in the future.
Enzyme-based amperometric microbiosensors
Enzyme-based amperometric microbiosensors are typically real-
ized by a set of immobilized membranes on noble metal or
carbon-based electrodes (Fig. 1). In a first-generation biosensor,
an enzyme converts the analyte to an intermediary product,
which is then oxidized at the electrode [1]. The resulting current
flow is proportional to the analyte concentration. The enzyme
proteins have to be immobilized in a matrix or membrane with-
out their functionality being lost. Most commonly, these are ox-
idase enzymes (e.g. glucose oxidase [21–23], lactate oxidase [21,
24–26], glutamate oxidase [26–29] or choline oxidase [29, 30]),
which convert their respective analyte to hydrogen peroxide un-
der the consumption of oxygen as a natural co-substrate (Fig. 1).
Hydrogen peroxide can be efficiently oxidized at polarized noble
metal electrodes (e.g. platinum) in a two-electron process [31].
Since other biogenic substances can also be oxidized at the elec-
trode, it is often covered with a permselective membrane, which
prevents other substances from reaching the electrode [32].
One disadvantage of this sensor principle is the dependency
on oxygen, which has limited solubility in aqueous fluids, only
approximately 200 μM under physiological conditions. It is
always available only in lower concentrations within tissues
because of restricted supply by blood vessels and permanent
cellular consumption. Therefore when one is measuring higher
analyte concentrations, the aim is to achieve a diffusion-limited
regime by limiting analyte diffusion with another membrane.
Ideally, this membrane limits the transport of oxygen to a much
lesser degree than analyte diffusion, and thus allows an unal-
tered enzymatic reaction even at high analyte concentrations.
For example, to fully convert 20mMglucose, its diffusionmust
be limited by a factor of 100 with the mentioned oxygen con-
centration because of the 1:1 stoichiometry of the enzymatic
reaction. The enzyme is typically loaded into the enzymemem-
brane in high concentrations so that the sensor performance is
not kinetically limited by the enzymatic reaction but by diffu-
sion of the analyte only. Oxygen dependencymay not affect the
measurement of low-concentration neurotransmitters, but it is
crucial for glucose or lactate monitoring.
With the goal to eliminate oxygen dependency, second-
generation, reagentless biosensors use an additional electron
acceptor (mediator) as a substitute for oxygen [1]. In this prin-
ciple, the enzyme is reduced and the substrate is converted to
the product. Then, the reduced form of the enzyme reduces the
mediator and is in turn oxidized by an intermolecular electron
transfer. In the final transduction step, the mediator is oxidized
at the electrode, resulting in electron transfer to the electrode.
Redox polymers can contain both an enzyme and a mediator
[33, 34]. In third-generation biosensors, the electron transfer
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Fig. 1 Enzyme-based, first-generation biosensor principle on
microelectrodes with glutamate as an example and a typical planar
electrode arrangement as found in microsensors. The analyte diffuses
into the membranes together with oxygen. The enzyme is immobilized
in the enzyme membrane and converts the analyte to hydrogen peroxide.
The hydrogen peroxide diffuses to the electrode, where it is oxidized at
the appropriately polarized electrode, generating the measured current.
Interferents are held back by the permselective membrane and cannot
be oxidized at the electrode, generating no additional signal. The
diffusion-limiting membrane can limit the transport of the analyte in
relation to the oxygen transport if the linear range has to be extended.
The working electrode contains the enzyme and measures the selective
signal. The blank electrode is similar only without immobilized enzymes.
It measures only the unspecific background, and its signal is subtracted
from that of the working electrode. Electrodeposited Ag/AgCl can serve
as a pseudo-reference electrode for the polarization of the working
electrode. GlOx glutamate oxidase
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mediators or a co-substrate but with often limited efficiency of
the electron transfer [1].
Microfabrication technology allows the efficient, parallel fab-
rication of small sensor devices [35]. Metal microelectrodes can
be precisely structured on silicon [29], ceramic [28] or polymeric
[21] substrates by lithography. Large numbers of electrodes can
be modified in parallel by electrodeposition processes. These
may include the deposition of silver and its conversion to silver
chloride (AgCl) for the integration of a pseudo-reference elec-
trode. The deposition of membranes, with or without enzymes,
as liquids with subsequent cross-linking can be performed pre-
cisely and in low volumes (microlitre to nanolitre range) by
dispensing or coating processes. Finally, individual devices can
be shaped by wafer-level etching [29] or automated cutting [26].
An overview is given in Table 1, and the different sensor systems
are discussed in BAmperometric microsensor platforms^.
Instrumentation
The output value of an amperometric sensor is the current for an
applied constant potential. Thus amperometric sensors are oper-
ated in electrochemical non-equilibrium. The simplest case is the
polarization of two electrodes, a working electrode and a com-
bined reference/counter electrode. In many cases, electrochemi-
cal in vivo sensors are operated this way [23, 24, 42, 45].
However, a combined reference/counter electrode should be sub-
stantially larger than the working electrode to show a potential
independent of the current. On one hand, such an electrode
should be involved in a redox reaction with high exchange cur-
rent density to ensure a stable potential, whereas on the other
hand, only inert electrodes prevent change or even consumption
of the electrode material due to the sensor current. Therefore
microsensors should preferably use a three-electrode setup with
a separated reference electrode and counter electrode [22, 26,
29]. The reference electrode (e.g. Ag/AgCl) is kept currentless,
whereas the counter electrode can be inert (e.g. Pt).
In such three-electrode setups, the voltage between the
working electrode and the reference electrode is regulated to a
set value by a current flowing through the working electrode
and the counter electrode. The current is the sensor output and
represents in the ideal case the conversion of the analyte only.
This type of circuit (and often also the corresponding device
including a data acquisition unit) is called a Bpotentiostat^. To
measure low current levels, two possible influences of electrical
noise have to be considered: one influence is on the stability of
the feedback loop in the regulation circuitry and the other one is
a noisy output signal. The first influence is more crucial and has
to be dampened appropriately in the analogue circuit. As a worst
case, the working electrode is polarized with an inappropriate
potential. From the perspective of measurement technology, it
would be favourable if the potentiostat circuitry (or at least the
analogue part) were in the direct vicinity of the sensor electrodes.
For in vivo experiments, sometimes headstages are used, pream-
plifiersmounted directly on the animal [45–47], mostly to reduce
noise in the connection lines in freely moving animals. If the
device is remote, all the wiring is within the feedback loop of
the potentiostat circuitry and is therefore sensitive to noise, which
may cause instability. In amperometry with constant potential or
chronoamperometric protocols using stepwise constant poten-
tials to precondition electrodes, the circuits do not have to be
faster than the acquisition rate. That is especially helpful for
low signals in a noisy environment because the bandwidth of
the feedback loop can be limited to low frequencies.
Several approaches to fabricate integrated potentiostats
have been described in the literature [48–51]. There are some
integrated circuits providing potentiostat functions available
Table 1 Overview of selected electrochemical amperometric microsensor platforms for in vivo measurement, including substrate type/material,
electrode material, realized sensor parameters and applied sensor immobilization/interference rejection methods
Substrate Electrode Parameter Sensor immobilization Interference rejection References
Wire/disc Pt/Ir Glu, L BSA + GA Nafion, AAOx [24, 27]
Pt/Ir Glu, G, L, Ch BSA + GA Nafion, AAOx [36, 37]
Ceramic Pt Glu, L, Ch, ACh, Ad BSA + GA PPD, Nafion [25, 28, 38, 39]
Carbon fibre C Glu Redox hydrogel Nafion, AAOx [33]
C Glu Redox hydrogel Nafion, AAOx [34, 40]
C/Ru G, L, Glu BSA + GA PPD, Nafion [22]
C L BSA + GA CA [41]
Silicon Pt Glu, Ch BSA + GA mPD [29]
Pt Glu BSA + GA PPy, Nafion [42, 43]
Pt G, L BSA + GA, PEGDE PPD [23]
Polyimide Pt G, L, Glu, O2, pH PHEMA, BSA + GA PPD [21, 26, 44]
AAOx ascorbate oxidase,ACh acetylcholine, Ad adenosine, BSA bovine serum albumin,CA cellulose acetate, Ch choline,G glucose,GA glutaraldehyde,
Glu glutamate, L lactate, mPD m-phenylenediamine, PEGDE poly(ethylene glycol) diglycidyl ether, PHEMA poly(hydroxyethyl methacrylate), PPD
polyphenylenediamine, PPy polypyrrole
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on the market (LMP 91000, Texas Instruments). However, to
our knowledge, there are no reports of the application of such
devices in an in vivo experiment. The integration of circuits
into the sensor device is, however, in contradiction to the
concept of disposablity behind microsensors.
Alternative methods
In the discussion of the use of microsensors in vivo, the question
arises if the use of such an invasive method can be justified, and
what particular advantages are to be expected. Certainly, a num-
ber of alternative techniques to measure metabolites in vivo are
available, with many of them being used widely in clinical prac-
tice (e.g. microdialysis or NMR methods). However, they differ,
often substantially, regarding what in the tissue is actually mea-
sured andwhere, andwhat analytical performance can be expect-
ed. Thus comparison with other techniques (summarized in
Table 2) not only helps to select the right approach for the appli-
cation but also helps to point out and discuss the advantages and
limitations of microsensor measurement.
Microdialysis
One of the most widely used in vivo techniques is microdialysis
[52, 53]. This fluidic method is used to sample and extract fluids
from tissues for external analysis. It has been used frequently in
animal models and humans, and also in clinical applications—
for example, traumatic brain injuries [54, 55]. In this invasive
method, a probe is inserted into the tissue, through which a fluid,
the perfusate, is pumped. An exposed semipermeable membrane
allows the exchange of analytes between the tissue and the fluid.
The perfusate with the analytes, the dialysate, is guided outside
the tissue and analysed externally, with a number of both online
and offlinemethods. In practice, theseminimally invasive probes
are, for example, double hollow fibres of around 250–500-μm
diameter and several millimetres long, where the perfusate enters
in the inner fibre and the dialysate flows back in the outer lumen.
The semipermeable membrane, with a cut-off of 5–50 kDa, is
exposed at the tip of the probe.
The efficiency of the extraction of the analyte from the tissue
depends on a number of factors, such as the probe andmembrane
geometry, the flow rate of the perfusion and the total sample
volume. Because of the diffusion through the membrane,
pumping and external analysis, this method always has a time
delay. One of the drawbacks of microdialysis is that the higher
flow rate and the lower the membrane area are, the higher the
temporal resolution and the spatial resolution become; however,
the concentration of the analyte in the dialysate becomes lower as
it is entirely dependent on its diffusion, and at zero flow, the
analyte concentration in the dialysate can become equal to the
tissue concentration at best. Novel fluidic methods such as use of
discrete droplets and segmented flow improve sample collection
[56, 57]. Separator fluids or gas bubbles segment the perfusate
into nanolitre-range droplets to prevent diffusion out of the small
Table 2 Comparison of different methods for in vivo measurement, comparing the invasive microsensor and microdialysis methods with the non-
invasive nuclear magnetic resonance, positron emission tomography and fluorescence imaging techniques
Method Advantages Disadvantages
Microsensors High temporal resolution (<1 s)
Low detection limit (<1 μM)





Limited number of analytes
Microdialysis Low detection limit (<1 nM)





Low temporal resolution (delay of seconds to minutes)
Fluidic setup necessary
Nuclear magnetic resonance Non-invasiveness
Direct detection of chemical structure
Large number of analytes
Low precision (mM)
High detection limit (mM)
Low temporal resolution (more than minutes)
Low spatial resolution (cubic millimetres to cubic centimetres)
Integral extracellular and intracellular values
Costly, large equipment
Positron emission tomography Non-invasiveness (except tracer)
Low detection limit (<1 μM)
Large number of analytes
Radioactive exposure
Tracer necessary
Low temporal resolution (seconds to minutes)
Low spatial resolution (mm3)
Costly, large equipment
Fluorescence imaging Low detection limit (<1 nM)
High temporal resolution (ms)
High spatial resolution (<1 μm)
Indirect via markers
Complex engineering of markers
Optical access needed
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confined volume. Zero-flow protocols can be applied in this way
without analyte dispersion.
In comparison with the in situ measurement with sensors, a
large number of powerful detection techniques are available
for external analysis of microdialysates. Offline methods such
as high-performance liquid chromatography or mass spec-
trometry offer superior analytical performance. That allows
the identification of a large number of different analytes with
high precision and low detection limits. However, offline anal-
ysis results in additional time delays and does not allow con-
tinuous monitoring. Online methods include use of electro-
chemical sensors and capillary electrophoresis. Yet, the time
delay even for rapid systems is still non-negligible. For elec-
trochemical sensors it ranges from 30 s to a few minutes [58,
59]. For online capillary electrophoresis with laser fluores-
cence detection, a temporal resolution of 12 s was reported
for glutamate measurement in animals [60]. A rise time of 60 s
was achieved by on-chip electrophoresis with amperometric
detection [61]. Still, the fast dynamics of some neurotransmit-
ters in combination with low concentrations are impossible to
measure by microdialysis. Additionally, the measurement of
dissolved gases with high diffusivities such as oxygen is very
cumbersome with external microdialysis methods because of
high out-diffusion during transport.
Nuclear magnetic resonance
Especially in the neurosciences, NMR techniques are used not
only for imaging but also to determine tissue concentrations of
metabolites. The advantage is the non-invasiveness. On the
basis of the alignment of nuclear spins in a strong magnetic
field and the absorption and reemission of non-ionizing elec-
tromagnetic radiation, NMR spectroscopy uses frequency
spectra to identify chemical compounds by their specific
chemical structure. Besides measuring protons for imaging,
this method also allows the direct detection of chemical com-
pounds. One difficulty here is the separation of structurally
related substances such as glutamate and glutamine, which
becomes harder at a lower magnetic field strength [62]. The
method can be enhanced by the labelling of molecules with
the isotope 13C, which often has to be injected because of its
low natural abundance and metabolized into the compounds
first [63, 64].
With regard to measurements in tissue, the principal differ-
ence between NMR spectroscopy and electrochemical
sensing/microdialysis is that NMR spectroscopy is a
volume-based method, which cannot discriminate between
extracellular and intracellular concentrations. For neurotrans-
mitters, where the difference between the two concentrations
is often particularly high, this limitation is consequently se-
vere. The regions of interest (voxels) that can be resolved are
rather large, usually in the range of 1–100 ml, compared with
the size of microelectrodes, [65–67]. The time to acquire
precise spectra is at least in the range of a few minutes, limit-
ing the temporal resolution of the method, with there being a
trade-off between sensitivity and temporal resolution. Exact
analytical performance is rarely ever discussed and calibra-
tions are often not shown. Compared with electrochemical
sensors, data suggest high detection limits, poor selectivity
and low precision, with high deviations of 10 % reported
[68]. This drawback is supported by the lack of studies of
the less-abundant substances present in concentrations lower
than the millimolar range. Thus, NMRmethods are more suit-
able to study long-term distribution, metabolic cycling and
storage of metabolites rather than fast transient changes at
low concentrations, which is usually the case for at least
neurotransmitters.
Positron emission tomography
Another clinically relevant method is positron emission to-
mography (PET). Radioactive tracer substances are intro-
duced into the tissue, fromwhich the emitted gamma radiation
is then detected. Species such as 15O or fluorodexoyglucose
(FDG), where 18F is bound to a glucose molecule, are used as
tracers. Apart from the tracer itself, the method is non-inva-
sive. The disadvantages of the method are that tracers with
limited availability and lifetime have to be administered to
the organism first and, in the case of FDG,metabolized, which
takes at least several minutes. FDG is taken up into cells but
unfortunately not metabolized further. The reported spatial
resolution is in the range of 2.5–3 mm [69, 70], limited by
the physical principle, and the acquisition rates are approxi-
mately one measurement per minute [71]. For mapping re-
gional cerebral oxygen distribution (e.g. after stroke) 15O
PET is considered a standard. Dopamine can be measured
by PET because its precursor dihydroxyphenylalanine can
be labelled with 18F. Furthermore, performance is dependent
on the local concentration and the binding of the tracer to the
target molecule. New tracers are under development for map-
ping in the context of neurodegenerative diseases [72].
Optical methods
Optical and fibre optical (bio)sensors, enzymatic and non-enzy-
matic, based on fluorescence or spectroscopy, including numer-
ous different transduction principles, have been reviewed in de-
tail elsewhere [73–75]. Few miniaturized systems for in vivo
application outside the field of glucose monitoring have been
realized, possibly because of the lack of appropriate fluorescent
dyes for the desired analytes. Still, it is very likely that optical
sensorswill play a larger role in the future. Particularly interesting
are approaches measuring non-invasively through the skin (e.g.
direct near-infrared sensors), although they are not applicable
everywhere, especially not in the brain, and are impaired by
changing optical path length and interferences.
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Especially for glutamate in the neuroscience context, so-
called sensors based on fluorescence markers in the tissue
have emerged [76–79]. These markers are introduced into
the cells and feature a glutamate-binding protein along with
a fluorescent protein. Evaluation by multiphoton fluorescence
microscopy yields astonishing analytical performances with
millisecond temporal resolution, areas of interest in the
submicrometre range and submicromolar detection limits
[80]. The drawbacks lie in the complex engineering of the
marker into the organism by genetically encoding protein al-
terations, the limited dynamic range due to the non-linear




A simple way to shape microelectrodes is to use modified
wires and fibres, which provided many opportunities when
other microfabrication processes were not available. Wires
are often insulated by melting glass, capped off and then
polished to be used as microelectrodes. Other insulation ma-
terials such as polymers can simply be removed for a defined
length to expose the entire wire cylinder. Carbon fibres are
fixed inside an insulator (e.g. a glass capillary) and then
capped off at the tip.
Hu et al. [24, 27] introduced a platinum wire for lactate and
glutamate measurement in the rat brain. The principle and tech-
nology have since been commercialized by Pinnacle
Technology. The Teflon insulation around a platinum iridium
wire of 170 μm diameter was removed for 1 mm length. On
protection of the tip by epoxy, a 700-μm-long sensor cavity
around the exposed wire was formed. Stability was sufficient
for stereotaxic placement in the brain, but the sensor was
strengthened by its being glued into a glass capillary after 8–
12 mm. Later variants by Pinnacle Technology are almost iden-
tical and include a chloridated silver wire wound around the
sensing wire as a Ag/AgCl pseudo-reference electrode [36, 37]
(Fig. 2a). The group of O’Neill used Teflon-insulated 60–
250 μm platinum wires for their glucose [81] and glutamate
[82, 83] sensors based on immobilization of the enzyme in an
electropolymerized layer. They also compared platinum with
other electrode materials, such as gold, palladium and glassy
carbon [84].
In a similar fashion, carbon fibres were used not only for
direct measurement of, for example, dopamine, but also for
enzyme-based electrochemical detection in vivo. A 30 μm car-
bon fibre exposed for 500 μm and fixed with epoxy into an
insulating pulled glass capillary was used by Shram et al. [41]
as a lactate sensor. Detection was by hydrogen peroxide oxida-
tion. The enzyme lactate oxidase was deposited by dip-coating.
Schuvailo et al. [22] coated a fibre with ruthenium to fabricate
oxidase-based glutamate, lactate and glucose sensors. In vivo
demonstration was limited however. The bienzyme approach
for 10-μm-diameter carbon fibres was used by Kulagina et al.
[33] and Oldenziel et al. [34, 85] for measurement of glutamate
and ascorbate in the rat brain. For reference, a comparable setup
of 5-μm-diameter carbon fibres, exposed for 50–100 μm, fixed
in glass capillaries was used to non-enzymatically measure do-
pamine inside the brain of rats [6].
The simplicity of fabrication has led to the wide use of
fibres and wires as in vivo sensors. Multielectrode arrays with
defined geometries are however difficult to realize (e.g. by
bundling of fibres) in comparison with sensors fabricated with
planar microtechnology. Manufacturing of sensors from fibres
and wires can be achieved with low-cost equipment, but effi-
cient, parallel mass fabrication is difficult or labour intensive.
Enzyme immobilization has been restricted mainly to dip-
coating, which allows only limited spatial control and impairs
the realization of multianalyte platforms or blank electrodes.
Sensor geometry is determined by the fibre/insulation dimen-
sions, and therefore restricts the overall length and the imple-
mentation of more complex geometric shapes.
Silicon-based platforms
The advancement of microfabrication technologies has trans-
lated increasingly into the development of silicon-based elec-
trochemical microsensors. Precise structuring of a large num-
ber of small electrode geometries on thin, needle-shaped de-
vices is possible, promising high spatial resolution and mini-
mal tissue damage. Besides the development of biosensors, it
has led even more to substantial developments of devices for
electrical recording from the CNS [86, 87]. Thin noble metal
layers can be deposited onto silicon wafers by physical vapour
deposition or sputtering and then structured by lithography
and a lift-off process. As insulation layers, different combina-
tions of silicon oxide or nitride are available, usually deposited
by chemical vapour deposition processes, with possible
plasma enhancement. Etching processes, such as reactive ion
etching, allow not only the creation of an electrode and contact
pad opening through the insulating layer but also the shaping,
thinning and release of the entire needle-type structures
in the wafer plane (e.g. by deep reactive ion etching).
Inconveniences are the need for costly equipment and clean-
room facilities for fabrication as well as the brittleness of sil-
icon, which limits the overall device length and robustness.
A silicon process was used by Frey et al. [29] for the fab-
rication of glutamate and choline microsensors for the brain of
rats (Fig. 2d). The silicon needles were 30–100 μm thick,
100 μm wide and 6.5 mm long, with the two working elec-
trodes located at the tip, and a Ag/AgCl reference electrode
was integrated further behind. The wafer-level processing in-
cluded the physical vapour deposition of platinum as the
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electrode material. Insulation was by provided by nitride de-
posited by chemical vapour deposition. Thinning from the
back side was by deep reactive ion etching, and shaping was
done from the front side. The electrodes recessed into the
nitride were of size 50 μm×150 μm. A single shaft or combs
of four shafts were connected by wire bonding. An almost
identical approach was pursued by Wassum et al. [43], also
for glutamate sensors. The probes were 150 μm thick and
120 μm wide and four 40 μm×100 μm working electrodes
were integrated. A reference electrode made from electrode-
posited iridium oxide was later integrated [42]. Another sili-
con platform for the simultaneous recording of glucose and
lactate in the brain was introduced recently [23]. Platinumwas
deposited by physical vapour deposition and 6-mm-long
microneedles with a 3 mm implantable part of 100 μm width
and 50μm thickness were shaped by deep reactive ion etching
from both sides. Insulat ion was achieved by the
photopatternable epoxy resist SU-8, omitting the need for ad-
ditional oxide/nitride deposition. This layer of 4 μm also
served as a recess for enzyme membrane integration on the
electrodes.
Ceramic-based platforms
Ceramic-based in vivo sensors for the brain have been exten-
sively developed and applied in the work by the group of
Gerhardt. They were based on 0.127-mm-thick ceramic sub-
strates with sputtered and lift-off patterned platinum metalli-
zation [28] (Fig. 2b). Thinner substrates (i.e. 25–50 μm) were
too difficult to use. A 10-μm-thick polyimide layer served as
the insulation. Needles were first shaped by rectangular dicing
of the ceramic substrate, and triangular shapes were produced
or tapering was done by laser cutting. A total length of up to
1 cm was reported, with the thickness increasing stepwise
from 125 μm [28] or continuously for the triangular shape
[25], with a sharp tip of 2–5 μm. Up to four working elec-
trodes of various geometries have been realized (e.g. square
50 μm×50 μm [28] or stretched to 15 μm×330 μm [88]). On
these microneedles, different amperometric biosensors for
glutamate [28, 45], lactate [25], choline [30] and acetylcholine
[38] have been realized. These sensors have been used in a
large number of neuroscience studies on both anaesthetized
[46, 89] and freely moving [47, 90] rodents.
By application of microfabrication technologies, needle-
type in vivo sensors were successfully realized on ceramic
substrates. As for silicon, brittleness limits the overall length
and minimum thickness. The number of available processes,
especially for etching into the depth of the material, is much
larger for silicon though. Most likely, the thin ceramic sub-
strate limits the reported size of the wafer/substrate
(2.5 cm×2.5 cm [88]), whereas in silicon, individual chips
can be thinned out and standard wafer sizes (e.g. 100 mm
diameter at 300 μm thickness) can be used. Dicing by blade
of the ceramic substrate allows only limited geometric shapes,
and additional, chip-level modifications such as laser cutting
are needed for final shaping.
Polymer-based platforms
The increase of biocompatibility and the ease of use of flexi-
ble, polymer-based platforms has is desirable for both in vivo
sensors and neurotechnological devices. One of the primary
limitations though is that unguided penetration into tissue (e.g.
into the brain in a stereotaxic setup) is not possible for very
16 mm
a) Wire c) Polymer









Fig. 2 In vivo microsensor
platforms. aModified wires or
fibres can be exposed and
enzymes immobilized on them
[36]. Microfabrication
technologies allow a more
efficient, advanced production
and sensor integration. Multiple,
small, recessed electrodes with
any geometry and layout can be
realized. Parallel
electrodeposition of membranes
and reference electrodes is
possible. Fabrication on b
ceramic [45], c polymer [26] or d
silicon substrates [29] for various
sensor shapes has been
demonstrated. (All images
reprinted with permission from
Elsevier)
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thin probes. Most developments in this field have been for
neural implants rather than biosensors. Still, an overview of
the technologies applied may be helpful for biosensor
development.
Polyimide resin can be spin-coated on silicon wafers and
sputtered with platinum as electrode material, which is then
insulated by another spin-coated polyimide layer [91].
Electrode opening and shaping of devices can be achieved
by reactive ion etching. Electrodes as small as 10 μm and with
a total thickness of less than 20 μm can be achieved.
Polyimide in a precursor state can also be laminated on such
structures to achieve additional layers [92]. As a shaft for an
optical waveguide, including a microchannel for drug delivery
into brain tissue of mice, 10 μm spin-coated polyimide as the
substrate was combined with 160-μm-thick SU-8 permanent
epoxy resist as the waveguide [93]. The SU-8 fluidic channel
was glued to the back side. The concept of rigid penetrators,
polyimide backed by silicon or metal, attached to integrated,
flexible polyimide cables was demonstrated for neural im-
plants [94, 95]. This principle is also potentially applicable
to microbiosensors. An all-polyimide probe for impedance/
resistivity measurement in the brain was developed [96]. On
top of the spin-coated 20 μm polyimide substrate, platinum
was sputtered and insulated by another 4-μm polyimide layer.
Electrode opening and shaping of the shaft was achieved by
dry etching. At a total length of around 30 mm and a width of
500μm, the device had to be supported by a glass capillary for
insertion. By the spin-coating of SU-8 onto a glass or silicon
substrate and subsequent release, shafts for neural recording
made entirely from SU-8 can be realized [97, 98]. Metal struc-
turing on the SU-8 was done by platinum sputtering and lift-
off or direct etching of gold and chromium. Up to five layers
of 20-μm-thick SU-8 were stacked, carrying up to four 20 μm
electrodes. The integration of a microfluidic channel for drug
delivery was also demonstrated with this technology [99].
Recording of DC signals was combined with amperometric
glucose and oxygen sensing [100]. The substrate was a spin-
coated polyimide of 12 μm thickness, with platinum working
and iridium oxide reference electrodes, which was spirally
rolled to form a 0.7 mm diameter tube-like structure.
For the fabrication of glucose and lactate biosensors in
pioneering work, we used a 100 μm polyimide film, vapour-
deposited platinum metallization, and insulation by another
2 μm polyimide layer [101]. Two working electrodes and a
Ag/AgCl reference electrode were included. Enzyme immo-
bilization was by entrapment in poly(hydroxyethyl methacry-
late)-based (PHEMA) hydrogels. Lactate sensors were later
added on a modified device [21]. For glutamate, glucose, lac-
tate and oxygen in vivo sensors for both the brain and subcu-
taneous applications, we used a polyimide film of thickness
between 50 and 100 μm and insulated the platinum electrodes
with 5 μm SU-8 epoxy resist on both sides [26, 44] (Fig. 2c).
Additionally, we introduced a laminated, 38-μm-thick
negative dry film resist as another layer. The main feature of
this relatively thick material is that it forms an even deeper
well around the electrode in comparison with that obtained
with other methods [23, 102], which allows volume control
during sensor membrane deposition. By the stacking of mem-
branes, the control of sensitivity and linear range is possible
for different enzyme immobilization techniques. The elec-
trode well also provides protection and limits crosstalk. This
hybrid approach combining thin-film and laminate technology
yields a flexible sensor strip which is still able to penetrate
brain tissue precisely without guidance up to length of
10 mm with a stereotaxic setup. A total device length of up
to 50 mm is possible for specific surgical applications. The
advantage here is that handling of the sensor is convenient
because the laminate is durable and there is no risk of break-
ing. Also, the sensor can flex along tissue or auxiliary struc-
tures during implantation. Both the length and the flexibility/
durability widen the field of application considerably, espe-
cially beyond use in the brain. Cutting of the sensors from the
polymer film wafer by a drag knife allows efficient shaping of
different geometries even after sensor integration and without
expensive dry etching or exposure to harmful chemicals and
heat. All together, this concept allows efficient mass fabrica-
tion of up to 76 sensors per wafer with relatively low cost
compared with other microfabrication technologies. Of
course, many of these advantages apply to flexible devices
in general.
Biosensor integration
Enzyme immobilization and sensor performance
The immobilization of the enzyme and modification of the
electrode are undoubtedly the most important steps in the
construction of electrochemical biosensors. The enzyme
needs to be permanently fixed to the electrode, without a ma-
jor loss in activity, thus allowing a continuous and stable sen-
sor performance. This can be achieved by different tech-
niques, where the major concepts used for in vivo platforms
are chemical cross-linking by an active cross-linker, often
combined with a neutral matrix, entrapment in a hydrogel
matrix, and integration into an electrodeposited polymer layer.
Certainly, an abundance of other concepts and crossovers
thereof exist, which cannot all be covered within this article.
The layer in which the enzyme is immobilized affects both
sensor performance and biocompatibility and can thus be used
to modify both. For very sensitive sensors (e.g. for the neuro-
transmitter glutamate), the goal is to immobilize a high density
of active enzyme into a highly permeable membrane to
achieve the maximum signal. A simple monolayer of enzymes
is not enough as it is kinetically limited because of full cata-
lytic occupation of the enzyme molecules. So, a thin, yet
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three-dimensional, matrix with high loading has to be used to
generate a higher signal. The signal becomes highest at the
transition between diffusion limitation and kinetic limitation.
Therefore the more this matrix limits analyte diffusion, the
more the signal will decrease again.
For a sensor with a high linear range, the aim is to achieve
high oxygen diffusion compared with analyte diffusion,
resulting in a fully diffusion-limited operation mode. In the
enzymatic layer, the enzyme can be overloaded, which means
its concentration is higher than needed, which makes the sen-
sor less dependent on loss or degradation of parts of the en-
zyme. Together with an immobilization which traps and fixes
the enzyme stably in the membrane, long-term stable sensors
can be realized. Generally speaking, these implications mean
that there is very often a trade-off between high signals and/or
a fast response and a linear range and/or long-term stability.
The parameters which can be realized by amperometric bio-
sensors are limited to the available oxidase enzymes, at least
for first-generation biosensors.
A comparison of in vitro long-term stability is difficult be-
cause either data are not presented in the studies or methods are
not comparable. We believe long-term stability should be eval-
uated only under continuous measurement with the analyte
present. Calibrations and storage in buffer in between measure-
ments will most likely not yield the same results as continuous
measurements. In sensors where hydrogen peroxide is pro-
duced, the exposure of the enzyme to this hydrogen peroxide
contributes to the degradation of the enzyme and thus can lead
to a decrease in sensitivity. Also, the local pH change due to the
hydrogen peroxide oxidation at the electrode can play a role.
Both depend on the local concentration of hydrogen peroxide,
which of course depends on the analyte concentration, but vary-
ing proportions make comparisons difficult. The best indicator
might be the absolute current density obtained.
For the in vivo situation, it is even more challenging to
compare performance. In short-term experiments, calibration
is mostly done before the experiment, and a certain loss in
sensitivity is then accepted but not measured. To track the
change of sensitivity in vivo, an in situ calibration scheme
would be necessary. To make comparisons, it would also have
to be standardized. However, in situ calibrations are not even
possible for all parameters. For example, in the brain, the
neurotransmitter glutamate is taken up rapidly from the extra-
cellular space. Therefore injected reference concentrations
clearly result in a much lower concentration being measured
by the sensor [26, 28, 29]. Even for the different sensing
methods, most importantly microsensors versus microdialy-
sis, different measured absolute concentrations have been re-
ported [103, 104]. More complex calibration and referencing
schemes, such as comparison with blood values measured by
clinical analysers, are also not possible for substances whose
concentrations fluctuate quickly and locally, and are thus lim-
ited to mainly glucose and lactate. Comparisons with in vitro
calibrations done after the in vivomeasurementsmay suffer from
effects of the explantation procedure and are even sometimes
discouraged as misleading [25]. Maintaining the same interface
as in vivo is also challenging because substances desorb from or
leech out of the sensor membrane after explantation [105].
Cross-linking
The most straightforward method to immobilize enzymes is to
chemically cross-link them to a carrier matrix. The most com-
monly used homobifunctional cross-linker is glutaraldehyde
and the most commonly usedmatrix is bovine serum albumin.
The two reactive groups of glutaraldehyde connect to both the
enzyme and the matrix proteins. Usually, the enzyme is dis-
solved together with bovine serum albumin, and as the final
step before deposition, glutaraldehyde is added. Deposition is
often done by dip-coating, drop-coating or dispensing of
microdroplets. Cross-linking occurs as the droplet dries, and
additional membrane layers can be added later to increase the
total amount of immobilized enzyme. A diffusion-limiting
and/or selective membrane, such as Nafion or polyurethane,
can be added on top later to increase the linear range or selec-
tivity. This method allows a high enzyme concentration be-
cause of the low viscosity of the precursor solution. It has been
applied for all types of microsensor platforms, including
wires, fibres, and discs, and ceramic, silicon and polymeric
substrates (Table 3). Frequently, it has been used for the fab-
rication of glutamate sensors, where usually the aim is sensi-
tivity as high as possible because of the expected low in vivo
concentration. Besides glucose and lactate, sensors for choline
produced by immobilization of choline oxidase [29, 30] can
also be realized. One can measure acetylcholine by addition-
ally immobilizing acetylcholinesterase, which converts acetyl-
choline to choline [38]. The choline background must be
subtracted with use of a dual electrode. Recently, an adenosine
sensor was demonstrated that uses the dual electrode principle
with three different enzymes, where xanthine oxidase pro-
duces the hydrogen peroxide [39].
If we compare glutamate sensor performance data
(Table 3), the best example for high-sensitivity biosensors,
the maximum achievable sensitivity across different platform
seems to be somewhere around 2 nA mm−2 μM−1. This cor-
responds to roughly the same enzyme loading into the precur-
sor solution at around 100–200 U ml−1. A higher concentra-
tion leads to issues with solubility and too high viscosity. A
thicker membrane and thus higher absolute amount of enzyme
means diffusion limitation of the glutamate into the membrane
because of the increasing thickness. A future substantial in-
crease in sensitivity is unlikely without a radical change in the
approach. Addition of an electropolymerized layer on top,
either for interference rejection or for fixing of the enzyme,
leads to a decrease in sensitivity. The limit of detection for this
principle was repeatedly found to be several hundred
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nanomoles per litre (Table 3). Noise in and limited resolution
of the signal due to the low currents, as well as drift, play a role
here. The choline sensors, for which the immobilization is
similar, show performance data comparable to those for the
glutamate sensors (Table 3). The response time for this meth-
od is short and typically in the range of 1–5 s.
From a comparison of the linear range, it is obvious that
highly sensitive sensors have only a limited range of a few
hundred micromoles per litre, the same concentration range as
that of the available oxygen. It is also apparent that for sensors
where the linear range needs to be extended (i.e. the lactate
sensors in Table 3), sensitivity must be sacrificed. Also, the
criteria for linearity must be taken into consideration when one
is comparing sensor performance. We observed that by choos-
ing a different R2 (e.g. 0.997 instead of 0.999), we could easily
change the declared linear range by a factor of 3. In practice,
the dip-coating or drop-coating of thin polyurethane layers on
top of the enzyme membrane is a common method to increase
the linear range [23–25]. It is also possible to electrodeposit
the enzyme from a solution onto the electrode by application
of a positive potential, which attracts the negatively charged
protein [29, 108]. The enzyme needs to be fixed by cross-
linking or entrapment under another membrane afterwards.
Where data are available, they show that the oxidation of
hydrogen peroxide at the platinum electrode is not or should
not be the limiting factor for sensitivity, because higher current
densities for hydrogen peroxide can be achieved with a good
electrode quality (Table 3). Performance across the systems is
in the same window, and addition of a selective membrane
decreases the sensitivity. Still, the sensitivity for hydrogen
peroxide is not magnitudes higher, so it must be considered
in the design and performance evaluation of such sensors,
especially in combination with deposited membranes.
A drawback of the cross-linking method is the limited sen-
sor lifetime. A decrease in sensitivity under continuous oper-
ation of several percent per day is not uncommon [26].
Continuous long-term data are rarely shown though. Sensors
are operated near the kinetic limitation of the enzymatic
Table 3 Comparison of enzyme-based amperometric in vivo
microsensor performance (in vitro) across different platforms. Highly
sensitive glutamate/choline sensors, lactate sensors with a wide linear
range, and performance data for the intermediary product hydrogen
peroxide are included. Where no specific values are stated, they were
calculated from the data shown and may therefore be approximations.
The achieved sensitivity, limit of detection (LOD) and linear range are
stated for a given platform, the enzyme immobilization method used, the
electrode material and the interference rejection method









Glutamate Pt/Ir Wire GA + BSA 0.26 - - Nafion [27]
Pt Wire/disc BSA + PPD 0.32 0.1 PPD [83]
Pt Silicon GA + BSA 0.5 0.79 0.08 PPy + Nafion [106]
Pt/Ir Wire GA + BSA 0.88 - - x + AAOx [36]
Pt Silicon GA + BSA 0.95 0.42 0.1 PPD [29]
Pt Wire GA + BSA 1.03 - - PPD + Nafion [107]
Pt Silicon GA + BSA 1.52 0.32 0.3 PPy + Nafion [42]
Pt Polymer GA + BSA 2.16 0.22 0.15 PPD [26]
Pt Ceramic GA + BSA 2.23 0.52 0.8 PPD [45]
C Fibre PEGDE + RH 0.32 - 0.1 AAOx [33]
C Fibre PEGDE + RH 0.82 0.09 0.1 AAOx [40]
C/Ru Fibre GA + BSA 2.39 - - Nafion [22]
H2O2 Pt Ceramic None 1.76 0.27 - Nafion [28]
Pt Polymer None 3.8 <0.1 1 PPD [26]
Pt Silicon None 3.85 - 0.06 PPD + Nafion [107]
Pt Ceramic None 4.88 0.13 - None [28]
Pt Polymer None 8.92 <0.1 1 None [26]
Lactate Pt Ceramic GA + BSA + PU 0.008 78 20 PPD [25]
Pt/Ir Wire GA + BSA + x 0.01 - 5 x [37]
Pt Polymer PHEMA 0.011 - 20 PPD [21]
Pt Polymer PHEMA 0.021–0.256 2–15 1–10 PPD [26, 44]
C Fibre GA + BSA 0.009 - - CA [41]
Choline Pt Silicon GA + BSA 1.32 0.3 0.3 PPD [29]
Pt Ceramic GA + BSA 2.64 0.412 0.2 Nafion [30]
AAOx ascorbate oxidase, BSA bovine serum albumin, CA cellulose acetate,GA glutaraldehyde, PEGDE poly(ethylene glycol) diglycidyl ether, PHEMA
poly(hydroxyethyl methacrylate), PPD polyphenylenediamine, PPy polypyrrole, PU polyurethane, RH redox hydrogel, x not specified
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reaction; therefore a loss in enzyme activity immediately leads
to a loss in signal. The immobilization has been reported to be
stable though, in the sense that sensors can be stored in buffer
without loss in sensitivity for times on the order of 1 month.
For longer storage times, reduction in sensitivity was ob-
served, underlining the limitations of this immobilization
method [26, 29]. Reduction of the specificity of the enzyme
by the cross-linking has also been reported, an issue that is
rarely ever discussed [109]. For glutaraldehyde, a cross-
sensitivity to other amino acids was found, and poly(ethylene
glycol) diglycidyl ether was recommended as a milder linker,
leading to better specificity. Other work found the glutaralde-
hyde method to be sufficiently specific [104].
Hydrogels
For the entrapment into hydrogels, the enzyme can be dissolved
in an aqueous solution, alongside the hydrogel monomers,
cross-linkers, plasticizers and the photoinitiator. This liquid pre-
cursor solution can be dispensed onto the electrode or the elec-
trode can be coated with it. On UVexposure, the photoinitiator
starts polymerization connecting the monomers and the cross-
linker. Spatial photopatterning of the hydrogel is also possible
[21]. With PHEMA, glucose, lactate and glutamate and gluta-
mine sensors were realized [21, 26, 44, 110, 111]. By the stack-
ing of different layers upon each other, diffusion-limiting mem-
branes without an enzyme can be introduced, which are used to
expand the linear range of the sensor (Table 3). By variation of
the thickness of the enzyme membrane and/or the diffusion-
limiting membranes, the sensitivity and linear range can be
adjusted over a very wide range without compromising sensor
performance parameters other than the response time. Even
though glutamate oxidase can be immobilized this way, the
concentration of the enzyme cannot be high enough to achieve
highly sensitive signals comparable with those obtained with
the cross-linking method.
The PHEMA hydrogel stabilizes the enzymes very well,
regarding both the natural conformation and thus activity and
the confinement/fixation of the enzyme inside the membrane,
and therefore leads to long-term stable sensors, particularly for
otherwise difficult to immobilize lactate oxidase [26, 110].
Besides, the PHEMA membrane is mechanically durable
and stable, and maintains unaltered integrity throughout stor-
age in both buffer solutions and a dry environment for years,
and enzyme activity remains. It also has high hydrophilicity
and shows little protein adhesion, which results in high bio-
compatibility in complex environments, both in vitro and
in vivo. Limiting factors are the limited solubility of the en-
zyme in the precursor solution and its high viscosity, which
limits the enzyme concentration and makes nanolitre-scale
dispensing or drop-coating the only feasible way to bring the
membrane onto the electrodes.
The bienzyme, second-generation method using a redox
hydrogel [112, 113] was also realized for glutamate [33, 40,
85]. Glutamate oxidase was wired to the redox hydrogel con-
taining an osmium complex by the linker poly(ethylene gly-
col) diglycidyl ether. The second enzyme was horseradish
peroxidase. Ascorbate oxidase was also co-immobilized
to improve selectivity [114]. The performance was compara-
ble to that of the first-generation biosensors (Table 3), al-
though response time at more than 20 s was slower [40], most
likely due to diffusion limitation by the dense gel. The hydro-
gel was applied to carbon fibres by dip-coating. Not depen-
dent on the hydrogen peroxide oxidation at the electrode, the
applied potential can be lowered to −150 mV (vs Ag/AgCl)
[40]. The method was also applied for choline and acetylcho-
line sensors [115].
Electrodeposited polymers
Besides their use as permselective layers to reject interferents,
electrodeposited polymers can also be used to immobilize
enzymes. These thin polymer/composite membranes in the
range of 10 nm can entrap the active enzyme on the electrode
and block interfering substances at the same time [116].
In vivo sensors were primarily realized for glucose [117]. It
is questionable whether these thin membranes can immobilize
enough enzyme for high-sensitivity neurotransmitter sensors.
Another option is to dip the electrode into a solution contain-
ing the enzyme and bovine serum albumin, and deposit the
electropolymerized layer afterwards to fix the enzyme in
place. This method was applied for glutamate on platinum
wire and disc electrodes [82, 83, 118]. The sensitivity was
lower than for the cross-linking method (Table 3).
Interference rejection principles and selectivity
One of the key parameters of sensor performance is selectiv-
ity. Typically, selectivity means a high signal caused by the
measured analyte, compared with a low signal caused by the
unspecific background. Selectivity is particularly important
for in vivo application. Analyte concentrations are often low
or change rapidly over time. Also, a variety of other sub-
stances are usually present, often in an unknown concentration
and composition. Electrochemical sensors mostly rely on the
conversion of a substance at the electrode, where the current
generated is proportional to the analyte concentration. Either
the analyte itself is converted or an intermediate product is
converted. In the case of enzyme-based biosensors, very often
this intermediate substance is hydrogen peroxide. Thus to en-
sure selectivity, the reaction of interfering substances at the
electrode must be prevented.
One method is the applied electrochemical protocol itself,
which means the polarization of the electrode to an appropri-
ate potential. Most electrochemical sensors are based on the
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oxidation of the analyte or the intermediary product. On noble
metal electrodes, in a potential region where, for example,
hydrogen peroxide is oxidized, a large number of biogenic
substances are also oxidized, producing a comparable or at
least non-negligible exchange current density. These are most
prominently ascorbic acid, which is present in a relatively high
concentration in the brain [119], uric acid or catecholamine
neurotransmitters such as dopamine [7]. They can also be
certain drugs (e.g. acetaminophen). In redox-hydrogel-based
sensors, the applied potential can be kept lower (usually
around −100 mV vs Ag/AgCl) than for hydrogen peroxide
oxidation (+400 to +700 mV), which also reduces cross-
sensitivity [33]. The major reducible species in the biological
environment is oxygen, which is of course present in most
tissues under physiological conditions. The overpotential for
its reduction is, however, high enough on most common elec-
trode materials that no reduction occurs in competition with a
desired oxidation reaction [120, 121].
Another widespread method to increase selectivity is the
use of a permselective membrane, an additional layer on the
electrode, which prevents interfering substances from
reaching the electrode but allows the transport of the analyte
or intermediary product. The commonest methods here are
thin polymer membranes, with their effect based on size ex-
clusion or charge exclusion (e.g. electropolymerized
aminobenzenes or drop-coated Nafion), where small, un-
charged molecules such as hydrogen peroxide can pass
through and large interferents are rejected because of their
higher molecular weight or charge.
The most frequently used permselective membranes are
electropolymerized polymers. The monomers are dissolved and
then anodically deposited onto the electrodes, often by cyclic
voltammetry. Electropolymerized poly(o-phenylenediamine)
and poly(m-phenylenediamine) were introduced as antifouling
layers based on size exclusion [32] and have been used since.
They were used for the coating of platinum electrodes on poly-
meric substrates [21, 26, 44], ceramic-based sensor platforms
[122] and wires [107] and carbon fibres [115], deposited either
by cyclic voltammetry or by constant potential (Table 3,
interference rejection). They can also be used to immobilize the
enzyme in a selective polymer/enzyme composite layer. The
deposition on top of the enzyme layer was shown on silicon-
based devices [29]. Here, the efficiency was demonstrated for
glutamate and choline sensors, but the question remains how
the analyte efficiently reaches the enzyme if the blocking layer
is on top of the enzymemembrane. Electrodeposited polypyrrole
[43], polyphenol [123] and the lipid phosphatidylethanolamine,
applied by dip-coating [82], can be used as other size-exclusion
layers. Nafion can serve as a permselective membrane based on
charge. It was dip-coated on wires [27], carbon fibres [33], ce-
ramic substrates [28] and silicon [43], where it also acts as a
diffusion-limiting membrane. Different permselective mem-
branes for glutamate sensors based on platinum wire electrodes
were reviewed by Wahono et al. [107], among them poly(o-
phenylenediamine) and poly(m-phenylenediamine, polypyrrole,
and polyaniline, also in combination with Nafion. The best per-
formance for interference rejection was found for poly(m-
phenylenediamine) deposited by cyclic voltammetry. We also
found this material to be ideal. Not only does it reject large
molecules very well, it also does not limit hydrogen peroxide
diffusion too much. In our case, hydrogen peroxide transport
was still half of that on an unmodified electrode [26]. The process
itself allows homogeneous coating of a large number of elec-
trodes in parallel, because of its self-limitation. It exhibits good
stability, although continuous exposure to hydrogen peroxide
will lead to degradation of the layer over days.
To determine the performance of permselective layers, se-
lectivity is often measured by the ratio of the sensitivity for the
analyte to the sensitivity for the interferent. However, if the
electrode sensitivity for the interferent is inherently low, this
ratio becomes high. Thus it can be helpful to determine the
sensitivity for the interferent on the unmodified electrode first
and then compare it with the sensitivity obtained with the
permselective membrane to directly evaluate its effect. Also,
it has to be considered that the interferent (e.g. ascorbic acid)
may react with hydrogen peroxide when the analyte and
interferent are measured together. Therefore we found it prac-
tical to measure the interferent alone first.
The specific nature of enzymes is obviously the reasonwhy
they are used as the sensor recognition element on the working
electrode and they therefore inherently contribute to the selec-
tivity. The immobilization of a second enzyme which breaks
down typical interferents is another way to further increase
selectivity. Ascorbic acid oxidase immobilized on top of the
sensing enzyme membrane to break down ascorbic acid from
the brain has been frequently used along with glutamate or
glucose oxidase for this purpose [27, 33, 36, 85].
Finally, the blank electrode principle is another way to in-
crease selectivity. A second electrode, ideally with the same
membrane setup as the working electrode, only without the en-
zyme, is implemented. The current of the blank electrode is then
subtracted from the signal of the working electrode [26, 28, 29,
110].With this method, it is possible to reduce not only chemical
interference but also long-term effects on background currents
(e.g. due to electrochemical processes in the electrode material
[124]), electrical noise coupling into both electrodes or general
effects such as offsets due to changes in temperature or humidity.
Particularly in the in vivo application, with a number of often
unknown and fluctuating background signals present, the imple-
mentation of a blank electrode can be very useful.
Biocompatibility
Without doubt, biocompatibility is and remains one of the
primary aspects and grand challenges for in vivo sensing.
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Despite its importance, within this scope, we can give only a
short overview of the topic and general perspectives for
microsensors. The term Bbiocompatibility^ itself has been de-
fined and refined to a great extent [125–127], so we will sim-
ply regard it as the interaction between the organism and the
sensor device which affects the functionality of the sensor.
One of the main reasons why biocompatibility is so important
for chemical and biosensors is that there is quantitative ex-
change of molecules, not only charge, across the interface
between the sensor or sensing element and the organism.
This transfer and the resulting sensor signal are in most cases
highly dependent on diffusion. Therefore changes at the inter-
face—these can encompass changes in the surrounding tissue,
adsorption or deposition of molecules at the interface or even
permeation into the membrane—will affect sensor perfor-
mance. The first goal must therefore be to achieve as little
change at the interface as possible.
Commonly, the reactions between the sensor and the host
organism are divided into different phases. First, within a few
seconds to hours, molecules, proteins or fragments thereof
adsorb to the sensor surface [105, 128]. A substantial decrease
in sensitivity during this phase has been reported, especially
for glucose. The exact reason for this decrease is still under
debate. The effect might not be as severe in a less demanding
environment (e.g. the brain) or for smaller analytes, for which
the diffusion is not limited as much. Experiments in the CNS
are often short term, so long-term stability has played a minor
role here to date. Molecules or fragments may migrate into the
sensor membrane, further reducing its permeability. Some of
the adsorption effects or biofouling is also reversible. When
one is comparing in vitro calibrations done before and after the
in vivo measurements, this subject must be considered. Over
the following days, a complex cascade of foreign body reac-
tions will be triggered, which includes the accumulation of
certain types of molecules and cells near the implant as part
of the inflammation reaction. This can lead to further impair-
ment of sensor function. Finally, an encapsulation of the im-
plant will occur, a phase where sensor performance is severely
affected but which in many cases is beyond the sensor lifetime.
To counter the above-mentioned issues, two main concepts
for sensor interfaces are pursued. These are the passive coat-
ing of the sensor interface with a multitude of different mate-
rials, or the active release of substances from the sensor mem-
brane material to mitigate the foreign body reaction. All sen-
sors shown in Table 3 feature the passive method. The poly-
mer membranes immobilizing the enzymes or ensuring selec-
tivity act to increase biocompatibility, mostly from the sensor
perspective in terms of maintaining sensitivity and prolonging
operation. So far, little effort has been put into trying to coat
the entire device with a more biocompatible layer to increase
overall biocompatibility. Magnetron-enhanced plasma-poly-
merized nanofilms are prospective candidates, as they allow
batch processing at room temperature after sensor integration
[129]. Among the active methods, the release of nitric oxide
from the sensor membrane is a promising concept to increase
the long-term stability of glucose sensors [123, 130–132]. The
location of placement for all in vivo sensors has almost exclu-
sively been the interstitial fluid, not the bloodstream. Because
of its complexity, blood provides a harsher and more difficult
environment for the sensor. A sensor in the bloodstream also
poses a risk for the host organism because of its
thrombogenicity. If sensors in the bloodstream are desired,
future work must solve both challenges.
Furthermore, it has become more and more evident that
true long-term biocompatibility means sensor flexibility and/
or elasticity must be matched with that of the surrounding
tissue [133]. Obviously, for metal needles or probes made of
materials such as silicon or a ceramic, but also for most poly-
mers, such as polyimide, the elastic modulus is still several
magnitudes higher than that of tissue, especially that of the
CNS [134]. Of course, the main reason why microsensors are
still more or less rigid and much stiffer than tissue is that they
need to be inserted into the said tissue, preferably without any
guiding structures and with high precision. Yet, more effort
can certainly be directed towards the integration of biosensors
on highly flexible/elastic materials and the design and fabri-
cation of such in vivo platforms, as well as towards the devel-
opment of new sensor device placement or insertion concepts
(e.g. dissolving inserter vehicles come to mind). With increas-
ing long-term stability of biosensors, this topic of structural
biocompatibility might become even more important.
Conclusions
Having discussed the different aspects of application,
microfabrication, sensor integration and performance of min-
iaturized amperometric in vivo biosensors, we wish to express
our concluding thoughts and outline future tasks for the vari-
ous topics. In doing so, we wish to address the engineering
perspective as well as the application perspective.
Microtechnology offers a multitude of possibilities to fab-
ricate and integrate microsensor platforms for in vivo applica-
tion. Particularly in silicon technology, new platforms have
emerged, based on recently optimized fabrication pathways.
Wafer-scale processing, including reference electrode integra-
tion, and even membrane/sensor integration can mean an ef-
ficient mass fabrication of ready-to-use devices. The develop-
ment of new sensing principles, however, is often done on a
macroscopic scale. There must be a translation of these prin-
ciples to usable platforms so that sensors do not share the
common fate of remaining Blaboratory curiosities^ [135].
The amperometric in vivo biosensors discussed here all em-
ploy fairly traditional sensing principles. Thousands of new
enzyme immobilization concepts and electrode materials are
developed that have surprisingly little impact on sensor
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performance. Many basic sensors are developed without even
an attempt being made to solve a performance problem or
without the opportunity being offered to apply them on micro
platforms. The relatively conservative in vivo sensor princi-
ples also show that the performance needs to be proven and
characterized well before in vivo use, and the platform needs
to be very reliable. The challenge clearly lies in the complete
package from platform design and sensor integration to a fea-
sible applicability.
With the available technology, platform sizes are still con-
siderably larger than the cellular dimension. Accessing synap-
ses or even the intracellular space lies way in the future. Future
trends may go in this direction. Whether this development
includes enzyme-based electrochemical biosensors is ques-
tionable. They are powerful tools, yet there are number of
inherent disadvantages. An appropriate enzyme (or enzyme
system) must exist, and it must be immobilized in a stable
way. There is often a trade-off between sensitivity and quick
response, and long-term stability. If the enzymatic reaction
requires oxygen, a dependency is to be expected if oxygen
supply is restricted. Diffusion occurs to and through the sensor
membrane, so all signals are diffusion limited, with diffusion
coefficients constant by nature.
We did a comprehensive performance comparison for
enzyme-based amperometric in vivo microsensors (Table 3).
The key performance data, such as sensitivity, linear range
and detection limit, fall in a relatively small range, even across
platforms, electrode materials and immobilization methods.
Sensitivity of around 2 nA mm−2 μM−1 and a detection limit
below 1 μM are feasible. The Bselective membrane/platinum/
hydrogen peroxide/oxidase enzyme^ system seems to be fairly
optimized, with no obvious room for improvement. Increasing
the linear range means limiting diffusion and thus sensitivity.
Aside from the available and well-used oxidase enzymes, fu-
ture work may focus on new combinations of enzymes and
multielectrode approaches to realize new parameters.
Engineering of the membrane deposition process itself offers
a multitude of options and reproducibility and exact tailoring of
the sensitivity/linear range can be challenging. More long-term
data from continuous measurements are desirable especially for
highly sensitive sensors outside the glucose world, both in vitro
and in vivo. This can include comparisons of in vitro calibra-
tions done before and after the in vivo measurements or in situ
calibration as well as the identification of adsorbing substances.
The determination of sensor parameters such as sensitivity, lin-
earity, selectivity, and long-term stability as well as the exact
methods applied to determine these parameters should be com-
municated clearly and paid attention to. More harmonization in
this regard would be useful. The same is true for in vivo data.
Biocompatibility remains a crucial topic. In vivo ampero-
metric biosensor use is still limited to a few days. Passive
tailoring of the interface and the active release from the sensor
both leave immense room for future developments. Still, there
seems to be no single optimal strategy. Also here, more work
outside the field of glucose sensing would be useful. Further,
the controlled interaction of the sensor with the host organism
should be expanded from the mere interface to the entire de-
vice. More detailed investigations of the actual compounds
which are responsible for sensor degradation are desirable.
For quantitative long-term measurements, in vivo calibration
schemes are inevitable. Flexibility of the devices is an under-
represented aspect regarding structural biocompatibility. The
process of insertion is a challenge for flexible devices.
Potentiostats and instrumentation are essential for ampero-
metric sensor operation. Advanced electrochemical protocols
require more sophisticated instruments, which cannot be self-
made easily and which are different from those in neural re-
cording. Commercially available instruments are often large
and expensive. Measurements on freely moving animals re-
quire headstages, which are often available only for proprietary
sensors. The combination of disposable microsensors and min-
iaturized electronics leaves room for improvement.With regard
to portable or wireless sensors as well as multichannel sensors,
technological developments in this direction are necessary.
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